ストックスクリーナーアプリを入手
0.4909
0.99%
-0.0049
プレマーケット:
.51
0.0191
+3.89%
前日終値:
$0.4958
開ける：
$0.49
24時間の取引高:
67,412
Relative Volume:
0.75
時価総額：
$30.83M
収益：
$37.06M
当期純損益:
$-8.20M
株価収益率:
-3.6827
EPS:
-0.1333
ネットキャッシュフロー:
$-12.87M
1週間 パフォーマンス:
+6.53%
1か月 パフォーマンス:
-22.78%
6か月 パフォーマンス:
-39.48%
1年 パフォーマンス:
-40.13%
1日の値動き範囲:
$0.462
$0.5054
1週間の範囲:
$0.44
$0.5174
52週間の値動き範囲:
$0.435
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.4909 | 31.13M | 37.06M | -8.20M | -12.87M | -0.1333 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2020-09-17 | 開始されました | Jefferies | Buy |
| 2020-09-01 | 開始されました | SVB Leerink | Outperform |
| 2017-08-08 | 繰り返されました | Maxim Group | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-05-24 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 繰り返されました | MLV & Co | Buy |
| 2015-04-01 | 繰り返されました | MLV & Co | Buy |
| 2015-03-05 | 開始されました | MLV & Co | Buy |
| 2015-02-25 | 開始されました | WBB Securities | Speculative Buy |
| 2015-01-27 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Cytosorbents Corp (CTSO) 最新ニュース
CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l - AD HOC NEWS
CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus - AD HOC NEWS
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Cytosorbents Earnings Call Balances Progress and Pressure - TipRanks
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Transcript: CytoSorbents Q1 2026 Earnings Conference Call - Yahoo Finance
Cytosorbents Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cytosorbents Corp 1Q 2026: Revenue $8.86M, EPS ($0.08) — 10-Q Summary - TradingView
CYTOSORBENTS ($CTSO) Releases Q1 2026 Earnings - Quiver Quantitative
CytoSorbents (CTSO) posts wider Q1 2026 loss and flags going-concern risk - Stock Titan
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA path and Q1 2026 results - Stock Titan
CytoSorbents: Q1 Earnings Snapshot - marketscreener.com
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - Fidelity
CytoSorbents Q1 earnings preview - MSN
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Quantisnow
CTSO (Cytosorbents) revenue climbs 4.1% to $37.1M in Q1 but loss widens, shares flat.Earnings Yield Analysis - Newser
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CytoSorbents schedules May 13 webcast for Q1 2026 results - Stock Titan
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Aktiellt
CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Executive Compensation, Stock Options, and Corporate Governance Disclosure - Minichart
Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan
CytoSorbents implemented workforce and cost reduction program - TipRanks
Cytosorbents granted 180-day extension by Nasdaq to meet minimum bid price - Investing.com South Africa
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan
Cytosorbents (CTSO) Takes Regulatory Gamble While Insiders Remain on the Sidelines and Institutions Are Divided - Bitget
CytoSorbents Corp (HQE1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Corp (HQE1.MU) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents Corporation 2025 Annual Report: Blood Purification Technologies, Clinical Trials, and Regulatory Insights - Minichart
Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed - TradingView
CytoSorbents (NASDAQ: CTSO) outlines global blood purification push and FDA path - Stock Titan
Cytosorbents’ Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents (CTSO) Q4 2025 Earnings Transcript - AOL.com
CytoSorbents 2025 Financials: Q4 & Annual Revenue and Loss ReportNews and Statistics - IndexBox
Cytosorbents Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral By Investing.com - Investing.com Canada
H.C. Wainwright reiterates CytoSorbents stock rating at Neutral - Investing.com
CytoSorbents Reports 2025 Financial Results: Revenue Growth, Clinical Advances, and Path to Cash Flow Breakeven in 2026 - Minichart
CytoSorbents (CTSO) Reports Slight Revenue Increase and Strategi - GuruFocus
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory ... By GuruFocus - Investing.com Canada
CytoSorbents Corp (CTSO) Q4 2025 Earnings Call Highlights: Navigating Growth and Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents reports Q4 2025 earnings miss, shares dip - Investing.com Australia
Cytosorbents Corp (CTSO) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
1.94%
大文字化:
|
ボリューム (24 時間):